About Us

Neuro-Innovators is a veteran team of neurotech scientists, physicians, and executives who understand the risks and challenges of bringing neurologic drugs to market.

Our goal is to efficiently commercialize novel compound drugs engineered to enhance our brain’s neuroplasticity. 

We have assembled an experienced team of scientists, pharmacologists, clinicians, and businesspeople with decades of experience in the neurosciences. We have designed and are executing a capital efficient, go-to-market strategy for our first drug, NIV-001, which we expect to greatly improve the effectiveness of chronic stroke rehabilitation.

Board of Directors

Howison Schroeder

Co-Founder & CEO

Mark Cochran, Ph.D.


Lieut. Col. (ret.)
Peter Doyle, M.D.

Co-Founder & Chief Medical Officer

Blynn Shideler

Co-Founder & IP Counsel

Multidisciplinary Team

Ian Reynolds

VP Drug Development

Aura Kullman

VP Clinical Studies

Matt Burlando


Chris Doyle

Medical Advisor

Scientific Advisory Board

George Wittenberg, M.D., Ph.D.

Board Member

John Lazo, Ph.D.

Board Member